Real-World data shows promise for breast cancer combo therapy
NCT ID NCT06075758
First seen May 15, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study observed 175 adults with HR+/HER2- advanced or metastatic breast cancer in the Middle East who received ribociclib combined with hormonal therapy. Researchers tracked side effects and how well the treatment controlled the cancer over 18 months. The goal was to understand real-world safety and effectiveness, not to test a new cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Amman, 11941, Jordan
-
Novartis Investigative Site
Muscat, 111, Oman
-
Novartis Investigative Site
Al Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
Conditions
Explore the condition pages connected to this study.